Clinical Trial News and Research

RSS

BioClinica third quarter service revenues increase 4.1% to $16.6 million

BioClinica, Inc., a global provider of clinical trial management and technology solutions, today announced its financial results for the third quarter and nine months ended September 30, 2011.

From Clario 9 Nov 2011

NIH announces results from first large scale study on treatment of prescription opioid addiction

People addicted to prescription painkillers reduce their opioid abuse when given sustained treatment with the medication buprenorphine plus naloxone (Suboxone), according to research published in yesterday's Archives of General Psychiatry and conducted by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

9 Nov 2011

Maryland anesthesiologist named 2011 Researcher of the Year

Often on the mind of Gary Fiskum, PhD, are the more than 250,000 people in the U.S. who get resuscitated from cardiac arrest each year, the 6 million living with traumatic brain injuries, and the wounded warriors whose brain whose brains sustain enormous G-forces from roadside bombs in the war zone.

9 Nov 2011

EI-IC bypass surgery does not lower risk of stroke recurrence in patients with TIA

A surgical procedure aimed at bypassing a blocked artery that supplies blood to the brain did not lower the subsequent stroke rate after 2 years in people who previously had a minor stroke, compared to those who did not have the surgery.

9 Nov 2011

BioMimetic Therapeutics reports third quarter total revenues of $0.4M

BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and nine months ended September 30, 2011.

9 Nov 2011

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity Pharmaceuticals, Inc. today highlighted its recent clinical and business progress and announced its third quarter 2011 financial results.

9 Nov 2011

First-ever phase 1 clinical trial of rectal HIV-prevention drug

A topically applied microbicide gel containing a potent anti-HIV drug has been found to significantly reduce infection when applied to rectal tissue that was subsequently exposed to HIV in the laboratory, according to a new study by the UCLA AIDS Institute.

9 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

9 Nov 2011

First clinical trial that integrates LifeOnKey EHR, PHR with Target eCRF EDC software

Target Health Inc., and LifeOnKey Inc., are pleased to announce the initiation of the first clinical trial that integrates the LifeOnKey electronic health record (EHR) and Personal Health Record (PHR), with Target eCRF electronic data capture (EDC) software.

9 Nov 2011

Micromet third quarter total revenues decrease to $4.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

QRxPharma receives FDA written acceptance for review of MoxDuo IR NDA

QRxPharma Limited announced today it received written acceptance from the United States Food and Drug Administration (FDA) for review of the MoxDuo IR New Drug Application (NDA) filed earlier this year.

9 Nov 2011

Omeros third quarter net loss decreases to $6.5 million

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2011.

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

Boston Scientific reports positive long-term data from PERSEUS clinical program

Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.

9 Nov 2011

ScreenCell, Transgenomic sign collaboration and distribution agreement for CTC technology

Transgenomic, Inc. and ScreenCell, a privately-held company, today announced the signing of a perpetual, worldwide collaboration and distribution agreement for ScreenCell's Isolation Devices and Dilution Buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

9 Nov 2011

Kessler Foundation neuropsychologists receive National Multiple Sclerosis Society grants

Two neuropsychologists at Kessler Foundation Research Center were awarded more than $100,000 in grants by the National Multiple Sclerosis Society. Nancy Chiaravalloti, PhD, received $63,000 to conduct a pilot study, "Speed of Processing Training for Improving Processing Speed in Persons with MS".

8 Nov 2011

FDA grants Fast Track designation to Opexa's Tovaxin for treatment of SPMS

Opexa Therapeutics, Inc., announced today that its lead drug candidate Tovaxin® has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Secondary Progressive Multiple Sclerosis.

8 Nov 2011

Comprehend Systems closes $1.2 million seed round funding

Driven by increasing demand from drug and medical device developers for cost-effective and user-friendly data analytics tools, Comprehend Systems, Inc. closed $1.2 million in seed round funding to support further development of Comprehend Clinical, its clinical data visualization and analytics software.

8 Nov 2011